Cervical Cancer Vaccine
As per officials, cervical cancer ranks as the second most frequent among women aged 15 to 44. Today, India is set to launch its first vaccine, Human Papilloma Virus (HPV), to fight against cervical cancer.
During the last month, the Drugs Controller General of India (DCGI) granted the Serum Institute of India (SII) authorization to manufacture a vaccine against cancer which would be indigenously developed. This took place following the request of Prakash Kumar Singh, the director of Serum Institute, to the DCGI for its market authorization on June 15, when the vaccine had completed its second and third clinical trials successfully.
Reports suggest that the vaccine will cost less than foreign-based drug options currently available on the market for treating cancer. The affordability of every Indian household has been ensured. Additionally, in the current instance, there are two vaccines developed, i.e., HPV and Cervarix, each of which costs between 2800 and 3299 INR.